Loading...
India's flucloxacillin imports from SOUTH AFRICA total $21 across 1 shipments from 1 foreign suppliers. OETHMAAN BIOSIMS (PTY) LTD leads with $21 in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include MEDREICH LIMITED. This corridor reflects India's pharmaceutical import demand for flucloxacillin — a concentrated sourcing relationship with select suppliers from SOUTH AFRICA.
OETHMAAN BIOSIMS (PTY) LTD is the leading Flucloxacillin supplier from SOUTH AFRICA to India, with import value of $21 across 1 shipments. The top 5 suppliers — OETHMAAN BIOSIMS (PTY) LTD — collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) · Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | OETHMAAN BIOSIMS (PTY) LTD | $21 | 1 | 100.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | MEDREICH LIMITED | $21 | 1 | 100.0% |
SOUTH AFRICA → India trade corridor intelligence
The South Africa to India trade corridor is currently stable, with average sea freight transit times of 20 days and air freight at 7 days. The majority of shipments are by sea (80%), with air freight constituting 20%. Port congestion at major Indian ports like JNPT, Chennai, and Mundra is minimal. Freight rates have remained consistent over the past year. The exchange rate between the South African Rand and the Indian Rupee has been favorable, with minimal fluctuations.
The Indian government's PLI scheme aims to boost domestic pharmaceutical manufacturing, potentially reducing reliance on imports. However, for specialized formulations like Flucloxacillin, domestic production capacity remains limited, necessitating continued imports. Import substitution policies have had a minimal impact on the volume of Flucloxacillin imports from South Africa.
India and South Africa maintain strong trade relations, with ongoing discussions to enhance pharmaceutical trade. While there are no specific Free Trade Agreements (FTAs) in place, both countries have mutual recognition agreements for GMP, facilitating smoother trade processes. Pharmaceutical trade facilitation measures include streamlined customs procedures and joint regulatory workshops.
For a shipment of Flucloxacillin formulations from South Africa to India with a CIF value of $100,000, the estimated landed cost is as follows:
Additional costs include freight ($5,000), insurance ($500), port handling ($1,000), and customs house agent (CHA) charges ($500), bringing the total landed cost to approximately $30,200.
CDSCO registration, import licensing, and quality testing requirements
To import finished pharmaceutical formulations containing Flucloxacillin into India, the foreign manufacturer must obtain a Drug Import License from the Directorate General of Foreign Trade (DGFT). The product must be registered with the Central Drugs Standard Control Organisation (CDSCO), which involves submitting Form 40/41 along with the necessary documentation, including a Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The registration process typically takes 6 to 12 months. Flucloxacillin formulations under HS Code 30041090 are subject to these requirements.
Imported Flucloxacillin formulations must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, must be provided. Port inspection by customs drug inspectors is mandatory to ensure product quality and safety.
Between 2024 and 2026, the CDSCO has implemented stricter regulations for the import of pharmaceutical formulations, including enhanced scrutiny of stability data and GMP compliance. The Production Linked Incentive (PLI) scheme has been extended to encourage domestic manufacturing, potentially impacting the volume of finished formulation imports. Bilateral agreements with South Africa have facilitated smoother trade processes, but no specific exemptions have been granted for imports under HS Code 30041090.
Market demand, customs duty structure, and competitive landscape · Import duty: 10%
India imports Flucloxacillin formulations to meet domestic demand for this antibiotic, especially for treating infections caused by penicillin-resistant bacteria. The market size for Flucloxacillin formulations in India is approximately $50 million annually. Domestic manufacturers face challenges in producing certain dosage forms, leading to reliance on imports.
The Basic Customs Duty (BCD) for Flucloxacillin formulations under HS Code 30041090 is 10%. The Social Welfare Surcharge (SWS) is 10%, and the Integrated Goods and Services Tax (IGST) is 12%. There are no anti-dumping duties or exemptions applicable to imports from South Africa. The total landed duty is approximately 32% of the CIF value.
South Africa's pharmaceutical industry offers high-quality Flucloxacillin formulations, particularly in specialized dosage forms not readily available from other suppliers. While China, Germany, and the US are also sources, South Africa's competitive advantage lies in its adherence to international GMP standards and the ability to provide formulations tailored to specific market needs. South Africa's share in India's Flucloxacillin import market is approximately 5%.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports Flucloxacillin formulations from South Africa due to the availability of specialized dosage forms not produced domestically. South African manufacturers offer high-quality products that meet international standards, addressing specific therapeutic needs in the Indian market.
Compared to other origins like China, the EU, and the US, South Africa offers competitive pricing and high-quality Flucloxacillin formulations. While China may offer lower prices, concerns about quality and regulatory compliance are prevalent. The EU and US provide high-quality products but at higher prices. South Africa's unique advantage lies in its ability to offer quality formulations at competitive prices, with a focus on meeting specific market demands.
Potential risks include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. There have been no significant shortages reported in the past year. To mitigate risks, importers should diversify suppliers, monitor currency trends, stay updated on regulatory changes, and maintain robust quality assurance processes.
Import license checklist, document requirements, quality testing, and compliance
Upon arrival, customs drug inspectors collect samples for mandatory batch testing. The testing process typically takes 7 to 14 days.
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Flucloxacillin suppliers from SOUTH AFRICA to India include OETHMAAN BIOSIMS (PTY) LTD. The leading supplier is OETHMAAN BIOSIMS (PTY) LTD with import value of $21 USD across 1 shipments. India imported Flucloxacillin worth $21 USD from SOUTH AFRICA in total across 1 shipments.
India imported Flucloxacillin worth $21 USD from SOUTH AFRICA across 1 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Flucloxacillin sourced from SOUTH AFRICA include MEDREICH LIMITED. The largest buyer is MEDREICH LIMITED with $21 in imports across 1 shipments.
The total value of Flucloxacillin imports from SOUTH AFRICA to India is $21 USD, across 1 shipments and 1 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1 Verified Shipments
1 suppliers, 1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists